Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Kota MizunoMasatoshi SakuraiJun KatoKentaro YamaguchiRyohei AbeYuya KodaKeisuke KataokaTakehiko MoriPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2022)
Our study showed that letermovir prophylaxis significantly reduced the incidence of CS-CMVi and NRM in a real-world setting and that the CMV serostatus of the donor remained as a risk factor for CS-CMVi even under letermovir prophylaxis.